DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

Br J Cancer. 2007 Jan 29;96(2):189-95. doi: 10.1038/sj.bjc.6603515. Epub 2007 Jan 9.


Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacokinetics
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Clinical Trials as Topic
  • Humans
  • Magnetic Resonance Imaging / methods*


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Biomarkers, Tumor